The stock of Wave Life Sciences Ltd (WVE) has seen a -12.67% decrease in the past week, with a 6.30% gain in the past month, and a -45.40% decrease in the past quarter. The volatility ratio for the week is 10.15%, and the volatility levels for the past 30 days are at 10.19% for WVE. The simple moving average for the past 20 days is -2.86% for WVE’s stock, with a -35.45% simple moving average for the past 200 days.
Is It Worth Investing in Wave Life Sciences Ltd (NASDAQ: WVE) Right Now?
Moreover, the 36-month beta value for WVE is -0.97. Analysts have varying opinions on the stock, with 10 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for WVE is 123.02M and currently, short sellers hold a 9.49% of that float. On May 07, 2025, WVE’s average trading volume was 1.38M shares.
WVE) stock’s latest price update
Wave Life Sciences Ltd (NASDAQ: WVE)’s stock price has gone decline by -17.08 in comparison to its previous close of 7.73, however, the company has experienced a -12.67% decrease in its stock price over the last five trading days. zacks.com reported 2025-05-01 that Wave Life Sciences (WVE) doesn’t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts’ Opinion of WVE
Many brokerage firms have already submitted their reports for WVE stocks, with Cantor Fitzgerald repeating the rating for WVE by listing it as a “Overweight.” The predicted price for WVE in the upcoming period, according to Cantor Fitzgerald is $10 based on the research report published on April 29, 2025 of the current year 2025.
Wedbush, on the other hand, stated in their research note that they expect to see WVE reach a price target of $18. The rating they have provided for WVE stocks is “Outperform” according to the report published on April 08th, 2025.
Jefferies gave a rating of “Buy” to WVE, setting the target price at $26 in the report published on February 25th of the current year.
WVE Trading at -22.75% from the 50-Day Moving Average
After a stumble in the market that brought WVE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.70% of loss for the given period.
Volatility was left at 10.19%, however, over the last 30 days, the volatility rate increased by 10.15%, as shares surge +10.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.84% lower at present.
During the last 5 trading sessions, WVE fell by -12.67%, which changed the moving average for the period of 200-days by +11.87% in comparison to the 20-day moving average, which settled at $6.60. In addition, Wave Life Sciences Ltd saw -48.18% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at WVE starting from HENRY CHRISTIAN O, who sale 10,500 shares at the price of $9.77 back on Mar 20 ’25. After this action, HENRY CHRISTIAN O now owns 16,115 shares of Wave Life Sciences Ltd, valued at $102,574 using the latest closing price.
Christian Henry, the Director of Wave Life Sciences Ltd, proposed sale 10,500 shares at $9.77 during a trade that took place back on Mar 20 ’25, which means that Christian Henry is holding shares at $102,579 based on the most recent closing price.
Stock Fundamentals for WVE
Current profitability levels for the company are sitting at:
- -1.02 for the present operating margin
- 0.59 for the gross margin
The net margin for Wave Life Sciences Ltd stands at -0.9. The total capital return value is set at -0.46. Equity return is now at value -73.24, with -30.94 for asset returns.
Based on Wave Life Sciences Ltd (WVE), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -5.94.
Currently, EBITDA for the company is -101.74 million with net debt to EBITDA at 2.72. When we switch over and look at the enterprise to sales, we see a ratio of 6.57. The receivables turnover for the company is 76.16for trailing twelve months and the total asset turnover is 0.31. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.89.
Conclusion
To wrap up, the performance of Wave Life Sciences Ltd (WVE) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
